| Literature DB >> 34931333 |
Yvonne E Kaptein1, Elaine M Kaptein2.
Abstract
BACKGROUND: Management of acute decompensated heart failure (ADHF) requires accurate assessment of relative intravascular volume, which may be technically challenging. Inferior vena cava (IVC) collapsibility with respiration reflects intravascular volume and right atrial pressure (RAP). Subclavian vein (SCV) collapsibility may provide an alternative. HYPOTHESIS: The purpose of this study was to examine the relationship between SCV collapsibility index (CI) and IVC CI in ADHF.Entities:
Keywords: acute decompensated heart failure; inferior vena cava ultrasound; subclavian/proximal axillary vein ultrasound; tricuspid regurgitation
Mesh:
Year: 2021 PMID: 34931333 PMCID: PMC8799052 DOI: 10.1002/clc.23758
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882
Figure 1Ultrasound probe positions and ultrasound images of the subclavian vein (SCV) and inferior vena cava (IVC) with respiration. (A) Ultrasound probe positions: distal SCV images were obtained with patients lying supine at an incline of 30–45°. A linear array transducer was placed inferior to the lateral border of the right clavicle, aligned in the deltopectoral groove along the axis of the right arm to obtain a transverse view of the SCV at the junction with the proximal axillary vein. The IVC was imaged via the subcostal window in a longitudinal plane using the phased array transducer. (B) Ultrasound images of the subclavian artery (SCA) and SCV using the linear array transducer with color‐flow Doppler to ensure imaging of the appropriate vessel and to clarify SCV borders. (C) Ultrasound images of the IVC using the phased array transducer. Images are shown during expiration and inspiration. Maximum and minimum SCV and IVC diameters were measured perpendicular to the inner edge of the vessel walls as illustrated by the white lines. IVC diameters were measured 2 cm from the right atrium (RA) or distal to the hepatic vein (HV)
Patient characteristics
| Characteristic |
| ||
|---|---|---|---|
| Age, years | 66 (60–76) | ||
| Female | 16 (48%) | ||
| Male | 17 (52%) | ||
| Race | |||
| African American | 10 (30%) | ||
| White | 21 (64%) | ||
| Other | 2 (6%) | ||
| BMI, kg/m2 (at time of dry weight) | 28.1 (24.1–36.5) | ||
| History of HTN | 30 (91%) | ||
| History of CAD | 18 (55%) | ||
| Prior stents | 7 | ||
| Prior CABG | 8 | ||
| History of PAD/PVD | 5 (15%) | ||
| History of CKD | 21 (64%) | ||
| CKD Stage 2 | 1 | ||
| CKD Stage 3 | 14 | ||
| CKD Stage 4 | 5 | ||
| CKD Stage 5/ESRD | 1 | ||
| History of DM | 12 (36%) | ||
| History of AFib/AFL | 18 (55%) | ||
| History of OSA | 9 (27%) | ||
| History of valvular disease | 19 (58%) | ||
| Historical heart failure diagnosis | 30 (91%) | Lowest lifetime EF before admission | Most recent EF before admission |
| HFrEF (LVEF < 40%) | 20 (69%) | 21.9% ± 8.0% | 23.4% ± 7.6% |
| HFmrEF (LVEF 40%–49%) | 4 (14%) | 43.5% ± 2.1% | 45.0% ± 2.5% |
| HFpEF (LVEF ≥ 50%) | 6 (18%) | 56.5% ± 2.8% | 58.9% ± 5.4% |
| LVEF (most recent before admission) | 38.0% (23.0%–51.0%) | ||
| Type of cardiomyopathy (for HFrEF/HFmrEF) | |||
| Ischemic | 11 (46%) | ||
| Nonischemic | 11 (46%) | ||
| Mixed | 2 (8%) | ||
| Devices (PPM and/or ICD) | 11 (33%) | ||
| NYHA functional class (before admission) | |||
| I | 2 | ||
| II | 7 | ||
| III | 12 | ||
| IV | 7 | ||
| Not reported | 5 | ||
| NT‐proBNP on admission (pg/ml) | 5731 (2968–13277) | ||
| Troponin on admission (ng/ml) | <0.10 (<0.05–0.13) | ||
| Loop diuretic infusion received | 18 (55%) | ||
| Inotrope or pressor received | 9 (27%) | ||
| Differences between admission and discharge values | |||
| Weight, kg | −6.9 (−11.3 to −2.2) | ||
| Serum creatinine, mg/dl ( | 0.0 (−0.11 to +0.30) | ||
| NT‐proBNP, pg/ml ( | −216 (−5303 to +680) | ||
| NT‐proBNP, percent change | −10.1% (−59.8% to +32.7%) | ||
| Net intake minus output, ml | −6485 (−12256 to −3140) | ||
| Hospital length of stay (days) | 8 (5–12) | ||
| All‐cause 30‐day readmission or ED visit (unplanned) | 10 (31%) | ||
| Mortality after 12 months | 10 (30%) | ||
Note: Data presented as n (%), median (interquartile range), or mean ± standard deviation.
Abbreviations: AFib, atrial fibrillation; AFL, atrial flutter; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; ED, emergency department; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HTN, hypertension; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; OSA, obstructive sleep apnea; PAD, peripheral arterial disease; PPM, permanent pacemaker; PVD, peripheral vascular disease.
All patients with atrial fibrillation or atrial flutter were rate controlled. A recent article by Berthelot et al. reported that IVCmax and IVC CI were valuable to identify patients with HFpEF with high left ventricular filling pressures even in patients with sinus rhythm or atrial fibrillation.
Valvular heart disease is defined as at least moderate level regurgitation, at least mild level stenosis, or history of valve repair or replacement.
12 months from the date of patient enrollment.
Figure 2Patient recruitment. IABP, intra‐aortic balloon pump; IVC, inferior vena cava; SCV, subclavian vein; US, ultrasound
Figure 3Correlations of SCV CI to IVC CI with both relaxed breathing and forced inhalation. Black curved lines represent 95% confidence interval. (A) Correlation of SCV CI to IVC CI with relaxed breathing. R = .65, n = 36, p < .001. (B) Correlation of SCV CI to IVC CI with forced inhalation. R = .47, n = 36, p = .0036. CI, collapsibility index; IVC, inferior vena cava; SCV, subclavian vein
Figure 4Sensitivity and specificity for SCV CI cutoffs, as predictors for IVC CI < 20% or >50%, with relaxed breathing. Red circles represent sensitivity and blue squares specificity. Solid curves are sigmoidal fit to data, with values for sensitivity and specificity maxima and minima constrained to 100% and 0%, respectively. SCV CI cutoffs at which sensitivity and specificity are equal and maximal are indicated by the vertical line. (A) Sensitivity and specificity for SCV CI cutoffs, as predictors for whether IVC CI is <20%, suggesting hypervolemia. The SCV CI cutoff of <22% corresponded to equivalent sensitivity/specificity of 72% (AUC of ROC plot = 0.786 ± 0.076 [SE], n = 36, p = .000085). (B) Sensitivity and specificity for SCV CI cutoffs, as predictors for whether IVC CI is >50%, suggesting hypovolemia. SCV CI cutoff of >33% corresponded to equivalent sensitivity/specificity of 78% (AUC of ROC plot = 0.833 ± 0.091 [SE], n = 36, p = .000127). AUC, area under the curve; CI, collapsibility index; IVC, inferior vena cava; ROC, receiver‐operator characteristic; SE, standard error; SCV, subclavian vein
Figure 5Relationship of first encounter SCV and IVC collapsibility indices and maximum diameters to the severity of tricuspid regurgitation in acute decompensated heart failure. Panels A and B show the relationship of SCV CI and IVC CI to TR in the current study population with acute decompensated heart failure. Higher SCV CI (p = .022 Mann–Whitney) and IVC CI (p = .0012 Mann–Whitney) were seen with less than moderate TR, compared to moderate or greater TR. Panels C and D show the effect of TR on SCVmax and IVCmax. Lower SCVmax (p = .00097 Mann–Whitney) and IVCmax (p = .026 Mann–Whitney) were seen with less than moderate TR, compared to moderate or greater TR in these patients with acute decompensated heart failure. Boxes represent medians and interquartile ranges. CI, collapsibility index; IVC, inferior vena cava; SCV, subclavian vein; TR, tricuspid regurgitation